Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 1
1948 11
1949 1
1951 8
1952 39
1953 50
1954 49
1955 33
1956 40
1957 42
1958 25
1959 21
1960 1
1961 4
1962 3
1963 8
1964 9
1965 78
1966 154
1967 179
1968 222
1969 243
1970 306
1971 214
1972 245
1973 268
1974 314
1975 204
1976 227
1977 149
1978 151
1979 158
1980 180
1981 150
1982 180
1983 177
1984 173
1985 208
1986 182
1987 183
1988 185
1989 223
1990 247
1991 241
1992 261
1993 304
1994 312
1995 409
1996 484
1997 454
1998 500
1999 492
2000 566
2001 592
2002 641
2003 670
2004 758
2005 793
2006 937
2007 997
2008 1011
2009 1098
2010 1258
2011 1448
2012 1622
2013 1717
2014 1804
2015 1812
2016 1863
2017 1914
2018 1905
2019 2058
2020 2172
2021 1995
2022 1764
2023 1494
2024 475

Text availability

Article attribute

Article type

Publication date

Search Results

39,228 results

Results by year

Filters applied: . Clear all
Page 1
The status of tuberculosis vaccine development.
Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. Schrager LK, et al. Lancet Infect Dis. 2020 Mar;20(3):e28-e37. doi: 10.1016/S1473-3099(19)30625-5. Epub 2020 Jan 31. Lancet Infect Dis. 2020. PMID: 32014117 Review.
Tuberculosis represents the leading global cause of death from an infectious agent. ...Results from clinical efficacy trials, particularly a completed, phase 2b trial for preventing tuberculosis disease in people infected with Mycobacterium tubercul …
Tuberculosis represents the leading global cause of death from an infectious agent. ...Results from clinical efficacy trials, …
Pretomanid for tuberculosis: a systematic review.
Gils T, Lynen L, de Jong BC, Van Deun A, Decroo T. Gils T, et al. Clin Microbiol Infect. 2022 Jan;28(1):31-42. doi: 10.1016/j.cmi.2021.08.007. Epub 2021 Aug 14. Clin Microbiol Infect. 2022. PMID: 34400340 Free article. Review.
STUDY ELIGIBILITY CRITERIA: Quantitative studies presenting original data on clinical efficacy or safety of pretomanid. PARTICIPANTS: Patients with tuberculosis. ...Mean differences in efficacy outcomes between regimens across studies were calculated. RESULTS: Eight …
STUDY ELIGIBILITY CRITERIA: Quantitative studies presenting original data on clinical efficacy or safety of pretomanid. PARTICIPANTS: …
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.
Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Sterling TR, et al. MMWR Recomm Rep. 2020 Feb 14;69(1):1-11. doi: 10.15585/mmwr.rr6901a1. MMWR Recomm Rep. 2020. PMID: 32053584 Free PMC article.
Quality of evidence (high, moderate, low, or very low) from clinical trial comparisons was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. ...Treatment of drug-resistant tuberculosis. An official ATS/CD …
Quality of evidence (high, moderate, low, or very low) from clinical trial comparisons was appraised using the Grading of Reco …
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DAJ, Nyang'wa BT. Berry C, et al. Trials. 2022 Jun 13;23(1):484. doi: 10.1186/s13063-022-06331-8. Trials. 2022. PMID: 35698158 Free PMC article.
A shorter, less toxic and more efficacious regimen would improve outcomes for people with rifampicin-resistant tuberculosis. METHODS: TB-PRACTECAL is an open-label, randomised, controlled, phase II/III non-inferiority trial evaluating the safety and efficacy …
A shorter, less toxic and more efficacious regimen would improve outcomes for people with rifampicin-resistant tuberculosis. METHODS: …
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T. Deodhar A, et al. Arthritis Res Ther. 2019 May 2;21(1):111. doi: 10.1186/s13075-019-1882-2. Arthritis Res Ther. 2019. PMID: 31046809 Free PMC article.
Here, we report longer-term pooled safety and tolerability data for secukinumab across three indications (up to 5 years of treatment in PsO and PsA; up to 4 years in AS). METHODS: The integrated clinical trial safety dataset included data pooled from 21 randomize …
Here, we report longer-term pooled safety and tolerability data for secukinumab across three indications (up to 5 years of treatment in PsO …
Uses of polypills for cardiovascular disease and evidence to date.
Huffman MD, Xavier D, Perel P. Huffman MD, et al. Lancet. 2017 Mar 11;389(10073):1055-1065. doi: 10.1016/S0140-6736(17)30553-6. Lancet. 2017. PMID: 28290995 Review.
Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for …
Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike f …
New tuberculosis vaccines: advances in clinical development and modelling.
Weerasuriya CK, Clark RA, White RG, Harris RC. Weerasuriya CK, et al. J Intern Med. 2020 Dec;288(6):661-681. doi: 10.1111/joim.13197. J Intern Med. 2020. PMID: 33128834 Free article. Review.
Achieving 'End TB' prevention and care goals by 2035 will likely require a new tuberculosis vaccine. The tuberculosis vaccine development pipeline has seen encouraging progress; however, questions around their population impact and implementation remain. ...We provi …
Achieving 'End TB' prevention and care goals by 2035 will likely require a new tuberculosis vaccine. The tuberculosis vaccine …
Delamanid in the treatment of multidrug-resistant tuberculosis.
Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ. Gupta R, et al. Int J Tuberc Lung Dis. 2016 Dec 1;20(12):33-37. doi: 10.5588/ijtld.16.0125. Int J Tuberc Lung Dis. 2016. PMID: 28240570 Review.
Otsuka has been engaged in anti-tuberculosis drug development efforts for over 30 years, and is the leading private sector funder of tuberculosis (TB) research and development. Delamanid (DLM), discovered by Otsuka's scientists, has been shown to provide benefit wit …
Otsuka has been engaged in anti-tuberculosis drug development efforts for over 30 years, and is the leading private sector funder of …
Vitamin D: Immuno-modulation and tuberculosis treatment.
Selvaraj P, Harishankar M, Afsal K. Selvaraj P, et al. Can J Physiol Pharmacol. 2015 May;93(5):377-84. doi: 10.1139/cjpp-2014-0386. Epub 2015 Jan 19. Can J Physiol Pharmacol. 2015. PMID: 25744368 Review.
Tuberculosis (TB) is a major global health problem and often coincides with vitamin D deficiency. ...Supplementation with vitamin D in concert with treatment for TB may be beneficial with respect to minimizing the excessive tissue damage that occurs during the active stage …
Tuberculosis (TB) is a major global health problem and often coincides with vitamin D deficiency. ...Supplementation with vitamin D i …
Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities.
McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR. McAnaw SE, et al. Int J Infect Dis. 2017 Mar;56:194-199. doi: 10.1016/j.ijid.2016.11.423. Epub 2016 Dec 9. Int J Infect Dis. 2017. PMID: 27955992 Free PMC article. Review.
On June 17, 2016, RESIST-TB, IMPAACT, Vital Strategies, and New Ventures jointly hosted the Pediatric Multidrug Resistant Tuberculosis Clinical Trials Landscape Meeting in Arlington, Virginia, USA. ...A series of presentations were given that discussed site capacity …
On June 17, 2016, RESIST-TB, IMPAACT, Vital Strategies, and New Ventures jointly hosted the Pediatric Multidrug Resistant Tuberculosis …
39,228 results
You have reached the last available page of results. Please see the User Guide for more information.